Key points are not available for this paper at this time.
Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most prevalent drug form, especially for widely distributed anterior segment eye diseases (cataracts, glaucoma, dry eye syndrome, inflammatory diseases, etc.), because they are convenient and easy to apply by patients. However, conventional drug formulations are usually characterized by short retention time in the tear film, insufficient contact with epithelium, fast elimination, and difficulties in overcoming ocular tissue barriers. Not more than 5% of the total drug dose administered in eye drops reaches the interior ocular tissues. To overcome the ocular drug delivery barriers and improve drug bioavailability, various conventional and novel drug delivery systems have been developed. Among these, nanosize carriers are the most attractive. The review is focused on the different drug carriers, such as synthetic and natural polymers, as well as inorganic carriers, with special attention to nanoparticles and nanomicelles. Studies in vitro and in vivo have demonstrated that new formulations could help to improve the bioavailability of the drugs, provide sustained drug release, enhance and prolong their therapeutic action. Promising results were obtained with drug-loaded nanoparticles included in in situ gel.
Building similarity graph...
Analyzing shared references across papers
Loading...
Alexander N. Vaneev
Victoria Tikhomirova
Н. Б. Чеснокова
SHILAP Revista de lepidopterología
International Journal of Molecular Sciences
University of North Carolina at Chapel Hill
Lomonosov Moscow State University
National University of Science and Technology
Building similarity graph...
Analyzing shared references across papers
Loading...
Vaneev et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69deaab0210a0977fce9506c — DOI: https://doi.org/10.3390/ijms222212368
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: